Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Operational Highlights
PFE logo

Pfizer Revenues Fall 6% on COVID Slump, Vyndaqel Surges 73% in Non-COVID Growth

PFE10-QFiling Date: 11/4/2025
Pfizer Inc.
Description

What this story covers

Pfizer's Q3 2025 revenues dipped 6% to $16.7B due to waning COVID demand, but non-COVID products like Vyndaqel (up 73%) and Eliquis (up 11%) drove resilience. Adjusted EPS rose to $0.87 amid cost savings. Strategic moves bolster pipelines. Strong liquidity supports dividends, though risks persist.

Story snapshot

CompanyPfizer Inc.
TickerPFE
VariantStandard detailed
Duration12:03
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0000078003-25-000150

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in